← Evidence map

ArticleAdvances in therapy2020

Response Letter to "Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China".

Haijing Guan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Response Letter to "Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China". | OpenQuestion